Doer Biologics, a clinical stage biopharmaceutical company developing therapies for metabolic diseases and cancers, has entered into a license agreement with BioNTech, granting BioNTech a worldwide license to use one of its discoveries to research, develop, manufacture, and commercialize biotherapeutics against an undisclosed target. Doer Bio will receive an upfront payment and will be eligible for potential development, regulatory, and commercial milestones.   “This license agreement wi...